It is an understatement to say that Martin Mackay is an industry veteran. The Rallybio Corp. CEO entered the field at the age of 16, later to return to advanced level studies. As he likes to note, he has had 31 bosses over his career, but has notably held top positions himself, at Alexion Pharmaceuticals Inc., AstraZeneca PLC and Pfizer Inc., where he helped develop and commercialize several ultra-rare and ultra-orphan therapies.
After a brief stint as a retiree, Mackay co-founded New Haven, CT-based Rallybio, a rare disease-focused biotech. He has shepherded the company into two significant co-development partnerships, several asset acquisitions and helped the company raise $182m before going public in the summer of 2021 and raising another $93m. (Also see "Rallybio Leverages Founders’ Experience, $145m In New Cash For Rare Diseases" - Scrip, 20 May, 2020
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
